MDMA-assisted psychotherapy has shown remarkable results in treating chronic, treatment-resistant PTSD, with 56% of participants no longer qualifying for the condition after just two to three sessions. This synthetic molecule, originally developed in 1912 by a pharmaceutical company, has a fascinating history that includes early military interest in mind control. The discussion highlights the potential of MDMA to challenge conventional psychiatric approaches to mental health treatment.
